Encompass Health Co. (NYSE:EHC) Stock Position Trimmed by WINTON GROUP Ltd

WINTON GROUP Ltd trimmed its position in Encompass Health Co. (NYSE:EHC - Free Report) by 33.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,729 shares of the company's stock after selling 4,804 shares during the quarter. WINTON GROUP Ltd's holdings in Encompass Health were worth $898,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of EHC. Segall Bryant & Hamill LLC lifted its holdings in shares of Encompass Health by 3.6% during the 4th quarter. Segall Bryant & Hamill LLC now owns 165,894 shares of the company's stock valued at $15,320,000 after acquiring an additional 5,757 shares in the last quarter. Prudential Financial Inc. boosted its position in shares of Encompass Health by 1.7% in the fourth quarter. Prudential Financial Inc. now owns 43,426 shares of the company's stock worth $4,010,000 after buying an additional 735 shares during the period. Vanguard Group Inc. grew its stake in shares of Encompass Health by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 10,404,081 shares of the company's stock valued at $960,817,000 after buying an additional 138,196 shares in the last quarter. Stevens Capital Management LP purchased a new stake in shares of Encompass Health during the 4th quarter valued at about $257,000. Finally, LPL Financial LLC lifted its position in Encompass Health by 8.8% during the 4th quarter. LPL Financial LLC now owns 35,558 shares of the company's stock worth $3,284,000 after acquiring an additional 2,869 shares in the last quarter. 97.25% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling at Encompass Health

In related news, CAO Andrew L. Price sold 5,042 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $98.29, for a total value of $495,578.18. Following the sale, the chief accounting officer now owns 69,164 shares of the company's stock, valued at approximately $6,798,129.56. This trade represents a 6.79 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.10% of the stock is currently owned by insiders.

Encompass Health Stock Down 1.0 %

NYSE EHC traded down $1.00 on Thursday, hitting $101.08. 134,296 shares of the stock traded hands, compared to its average volume of 667,020. The company has a market capitalization of $10.18 billion, a P/E ratio of 22.66, a price-to-earnings-growth ratio of 2.31 and a beta of 0.92. The stock has a 50-day moving average of $99.07 and a 200 day moving average of $97.61. The company has a current ratio of 1.05, a quick ratio of 1.04 and a debt-to-equity ratio of 0.84. Encompass Health Co. has a twelve month low of $78.53 and a twelve month high of $104.55.

Encompass Health (NYSE:EHC - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.17 EPS for the quarter, topping analysts' consensus estimates of $1.05 by $0.12. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. As a group, analysts expect that Encompass Health Co. will post 4.8 earnings per share for the current fiscal year.

Encompass Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Tuesday, April 1st will be issued a $0.17 dividend. The ex-dividend date is Tuesday, April 1st. This represents a $0.68 dividend on an annualized basis and a yield of 0.67%. Encompass Health's dividend payout ratio is currently 15.25%.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on EHC shares. William Blair reaffirmed an "outperform" rating on shares of Encompass Health in a research report on Friday, February 7th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $110.00 price target on shares of Encompass Health in a research note on Tuesday, February 11th. Barclays upped their price objective on shares of Encompass Health from $116.00 to $118.00 and gave the company an "overweight" rating in a research report on Friday, February 7th. KeyCorp lifted their target price on Encompass Health from $117.00 to $120.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. Finally, StockNews.com raised Encompass Health from a "hold" rating to a "buy" rating in a report on Saturday, February 15th. Ten equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $107.67.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.